- Home
- CBRE vs KVUE Comparison
CBRE vs KVUE Comparison
Compare CBRE & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRE
- KVUE
- Stock Information
- Founded
- CBRE 1906
- KVUE 2022
- Country
- CBRE United States
- KVUE United States
- Employees
- CBRE N/A
- KVUE N/A
- Industry
- CBRE Real Estate
- KVUE Specialty Chemicals
- Sector
- CBRE Finance
- KVUE Consumer Discretionary
- Exchange
- CBRE Nasdaq
- KVUE Nasdaq
- Market Cap
- CBRE 40.1B
- KVUE 46.2B
- IPO Year
- CBRE 2004
- KVUE 2023
- Fundamental
- Price
- CBRE $128.86
- KVUE $21.50
- Analyst Decision
- CBRE Buy
- KVUE Hold
- Analyst Count
- CBRE 9
- KVUE 13
- Target Price
- CBRE $133.33
- KVUE $22.67
- AVG Volume (30 Days)
- CBRE 2.0M
- KVUE 12.3M
- Earning Date
- CBRE 02-13-2025
- KVUE 02-06-2025
- Dividend Yield
- CBRE N/A
- KVUE 3.81%
- EPS Growth
- CBRE 66.15
- KVUE N/A
- EPS
- CBRE 3.10
- KVUE 0.55
- Revenue
- CBRE $34,313,000,000.00
- KVUE $15,459,000,000.00
- Revenue This Year
- CBRE $13.52
- KVUE $2.89
- Revenue Next Year
- CBRE $11.01
- KVUE $2.80
- P/E Ratio
- CBRE $41.52
- KVUE $38.92
- Revenue Growth
- CBRE 10.00
- KVUE N/A
- 52 Week Low
- CBRE $82.75
- KVUE $17.67
- 52 Week High
- CBRE $142.00
- KVUE $24.46
- Technical
- Relative Strength Index (RSI)
- CBRE 37.87
- KVUE 25.99
- Support Level
- CBRE $136.01
- KVUE $21.76
- Resistance Level
- CBRE $140.70
- KVUE $22.48
- Average True Range (ATR)
- CBRE 3.09
- KVUE 0.59
- MACD
- CBRE -1.00
- KVUE -0.22
- Stochastic Oscillator
- CBRE 2.03
- KVUE 0.89
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About KVUE Kenvue Inc.
Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.